Trump Meets With Security Team After Demanding Iran ‘Surrender'
Good morning. The US is pushing Tehran to surrender in its conflict with Israel. It will be a long slog before the West can loosen China's dominance in critical minerals. And Honda has good news for fans of its out-of-production NSX supercar. Listen to the day's top stories.
Donald Trump raised the pressure on Iran and pushed for an ' unconditional surrender ' in its fight with Israel. Iran's Supreme Leader is safe 'for now' but 'our patience is wearing thin,' Trump said. The president met with his security team, fueling speculation that the US may join Israel's attack on Iran. Satellite images suggest Israeli strikes damaged Iran's underground uranium-enrichment facilities at Natanz. Israel's defense minister said the country plans to attack 'very significant targets' in Tehran. Investors were jittery: US stocks fell, oil rose and the dollar climbed the most in a month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
SunRun Stock Plunged 40% Tuesday—Watch These Key Price Levels
SunRun shares plummeted Tuesday, leading a steep sell-off in solar energy stocks after the Senate maintained the full removal of clean-energy tax credits in the budget bill. A chart pattern that closely resembles a falling three methods has recently emerged, signaling a continuation of the stock's long-term move lower. Investors should watch key support levels on SunRun's chart around $4.75 and $4.33, while also monitoring important overhead areas near $8.50 and $ (RUN) shares plunged Tuesday, leading a steep sell-off in solar energy stocks after the Senate maintained the full removal of clean-energy tax credits in its version of the budget bill. The move comes after SunRun and other bellwether solar names tumbled last month after the House passed a tax and spending bill that would end tax credits for wind and solar projects in 2029, years earlier than a previous version of the bill. Following today's development, Citi maintained its sell rating on residential solar stocks and cautioned that it expects a 'sharp pullback' in shares of SunRun, SolarEdge Technologies (SEDG) and Enphase Energy (ENPH). SunRun shares fell 40% on Tuesday, closing the session at $5.78. The stock has lost three-quarters of its value since hitting its 52-week high last August, weighed down by uncertainty surrounding the sector caused be policy changes, a clouded regulatory outlook and reduced demand. Below, we take a closer look at SunRun's weekly chart and use technical analysis to identify key price levels worth watching out for. Since topping out in early 2021, SunRun shares have remained entrenched in a steady downtrend, with losses in the stock accelerating after the 50-week moving average (MA) crossed below the 200-week MA in September 2022 to form a death cross. More recently, a chart pattern that closely resembles a falling three methods has emerged, signaling a continuation of the stock's long-term move lower. What's more, the relative strength index has fallen back below its neutral threshold, confirming a resumption of selling momentum. It's also worth noting that trading volume has increased in recent weeks, indicating growing interest in the stock from both retail and institutional investors. Let's identify two key support levels to watch on SunRun's chart if the price keeps falling and also locate overhead areas worth monitoring during future recovery efforts in the stock. Firstly, it's worth keeping a close eye on the key $4.75 level. This area may attract strong buying interest near an established floor of support that formed on the chart between October 2016 and May 2017. A breakdown below this level could see the shares drop to around $4.33. We projected this level by taking a look what happened when the stock dropped by more than 40% in a week during the March 2020 pandemic-driven sell-off. On that occasion, the shares dropped a further 25% the following week before staging a dramatic recovery. Therefore, a decline of a similar magnitude from Tuesday's close of $5.78 projects a downside target of $4.33, assuming the stock ends this week around its current trading levels. However, keep in mind this analysis is speculative, given the stock fell by more than 40% in a week last month and has kept moving lower. During recovery efforts in the stock, investors should monitor the $8.50 area. The shares may face renewed selling pressure in this region near prominent troughs that formed on the chart in March 2020 and October 2023. Finally, buying above this level could see an upswing toward $13.25. Investors who have bought SunRun shares at lower levels may seek to lock in profits at this location near last month's high, which also closely aligns with a range of corresponding trading activity on the chart extending back to mid-2018. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Here's Why Astera Labs, Inc. (ALAB) Fell More Than Broader Market
In the latest close session, Astera Labs, Inc. (ALAB) was down 2.51% at $92.91. The stock's performance was behind the S&P 500's daily loss of 0.84%. Meanwhile, the Dow lost 0.7%, and the Nasdaq, a tech-heavy index, lost 0.91%. The company's shares have seen an increase of 5.23% over the last month, surpassing the Computer and Technology sector's loss of 0% and the S&P 500's gain of 1.44%. The investment community will be closely monitoring the performance of Astera Labs, Inc. in its forthcoming earnings report. The company is expected to report EPS of $0.33, up 153.85% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $172.71 million, up 124.74% from the year-ago period. ALAB's full-year Zacks Consensus Estimates are calling for earnings of $1.35 per share and revenue of $702.43 million. These results would represent year-over-year changes of +60.71% and +77.25%, respectively. Investors should also note any recent changes to analyst estimates for Astera Labs, Inc. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 2.74% rise in the Zacks Consensus EPS estimate. Astera Labs, Inc. currently has a Zacks Rank of #2 (Buy). With respect to valuation, Astera Labs, Inc. is currently being traded at a Forward P/E ratio of 193.92. This expresses a premium compared to the average Forward P/E of 45.44 of its industry. One should further note that ALAB currently holds a PEG ratio of 4.48. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Internet - Software industry was having an average PEG ratio of 3.23. The Internet - Software industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 47, placing it within the top 20% of over 250 industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Astera Labs, Inc. (ALAB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Hologic (HOLX) closed at $64.14, marking a -1.6% move from the previous day. This move lagged the S&P 500's daily loss of 0.84%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw a decrease of 0.91%. Coming into today, shares of the medical device maker had gained 14.77% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 1.44%. The investment community will be paying close attention to the earnings performance of Hologic in its upcoming release. The company is expected to report EPS of $1.06, unchanged from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.01 billion, indicating a 0.39% downward movement from the same quarter last year. HOLX's full-year Zacks Consensus Estimates are calling for earnings of $4.2 per share and revenue of $4.08 billion. These results would represent year-over-year changes of +2.94% and +1.16%, respectively. Any recent changes to analyst estimates for Hologic should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.27% decrease. Hologic presently features a Zacks Rank of #4 (Sell). Looking at its valuation, Hologic is holding a Forward P/E ratio of 15.52. This denotes a discount relative to the industry average Forward P/E of 26.88. It is also worth noting that HOLX currently has a PEG ratio of 2.39. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.26 based on yesterday's closing prices. The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 151, putting it in the bottom 39% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
